Abstract
Purpose
Bupivacaine, levobupivacaine, and ropivacaine are amide local anesthetics. Levobupivacaine and ropivacaine are stereoisomers of bupivacaine and were developed to circumvent the bupivacaine’s severe toxicity. The recently characterized background potassium channel, K2P TREK-1, is a well-known target for various local anesthetics. The purpose of study is to investigate the differences in inhibitory potency and stereoselectivity among bupivacaine, levobupivacaine, and ropivacaine on K2P TREK-1 channels overexpressed in COS-7 cells.
Methods
We investigated the effects of bupivacaine, levobupivacaine, and ropivacaine (10, 50, 100, 200, and 400 μM) on TREK-1 channels expressed in COS-7 cells by using the whole cell patch clamp technique with a voltage ramp protocol ranging from −100 to 100 mV for 200 ms from a holding potential of −70 mV.
Results
Bupivacaine, levobupivacaine, and ropivacaine showed reversible inhibition of TREK-1 channels in a concentration-dependent manner. The half-maximal inhibitory concentrations (IC50) of bupivacaine, levobupivacaine, and ropivacaine were 95.4 ± 14.6, 126.1 ± 24.5, and 402.7 ± 31.8 μM, respectively. IC50 values indicated a rank order of potency (bupivacaine > levobupivacaine > ropivacaine) with stereoselectivity. Hill coefficients were 0.84, 0.93, and 0.89 for bupivacaine, levobupivacaine, and ropivacaine, respectively.
Conclusion
Inhibitory effects on TREK-1 channels by bupivacaine, levobupivacaine, and ropivacaine demonstrated stereoselectivity: bupivacaine was more potent than levobupivacaine and ropivacaine. Inhibition of TREK-1 channels and consecutive depolarization of the cell membrane by bupivacaine, levobupivacaine, and ropivacaine may contribute to the blockade of neuronal conduction and side effects.
Similar content being viewed by others
References
Zink W, Graf BM. The toxicity of local anesthetics: the place of ropivacaine and levobupivacaine. Curr Opin Anaesthesiol. 2008;21:645–50.
Groban L. Central nervous system and cardiac effects from long-acting amide local anesthetic toxicity in the intact animal model. Reg Anesth Pain Med. 2003;28:3–11.
Stewart J, Kellett N, Castro D. The central nervous system and cardiovascular effects of levobupivacaine and ropivacaine in health volunteers. Anesth Analg. 2003;97:412–6.
Zink W, Graf BM. Benefit-risk assessment of ropivacaine in the management of postoperative pain. Drug Saf. 2004;27:1093–114.
Mather LE. Stereochemistry in anaesthetic and analgesic drugs. Minerva Anestesiol. 2005;71:507–16.
Casati A, Putzu M. Bupivacaine, levobupivacaine and ropivacaine: are they clinically different? Best Pract Res Clin Anaesthesiol. 2005;19:247–68.
Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science. 1994;265:1724–8.
Kindler CH, Spencer Y, Gray AT. Local anesthetic inhibition of baseline potassium channels with two pore domains in tandem. Anesthesiology. 1999;90:1092–102.
Kindler CH, Paul M, Zou H, Liu C, Winegar BD, Gray AT, Yost CS. Amide local anesthetics potently inhibit the human tandem pore domain background K+ channel TASK-2 (KCNK5). J Pharmacol Exp Ther. 2003;306:84–92.
Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol. 2000;279:F793–801.
Kindler CH, Yost CS. Two-pore domain potassium channels: new sites of local anesthetic action and toxicity. Reg Anesth Pain Med. 2005;30:260–74.
Honoré E. The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci. 2007;8:251–61.
Nayak TK, Harinath S, Nama S, Somasundaram K, Sikdar SK. Inhibition of human two-pore domain K+ channel TREK1 by local anesthetic lidocaine: negative cooperativity and half-of-sites saturation kinetics. Mol Pharmacol. 2009;76:903–17.
Kim E, Hwang EM, Yarishkin O, Yoo JC, Kim D, Park N, Cho M, Lee YS, Sun CH, Yi GS, Yoo J, Kang D, Han J, Hong SG, Park JY. Enhancement of TREK1 channel surface expression by protein–protein interaction with beta-COP. Biochem Biophys Res Commun. 2010;30:244–50.
Leone S, Di Cianni S, Casati A, Fanelli G. Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. Acta Biomed. 2008;79:92–105.
Longobardo M, Delpón E, Caballero R, Tamargo J, Valenzuela C. Structural determinants of potency and stereoselective block of hKv1.5 channels induced by local anesthetics. Mol Pharmacol. 1998;54:162–9.
González T, Arias C, Caballero R, Moreno I, Delpón E, Tamargo J, Valenzuela C. Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block. Br J Pharmacol. 2002;137:1269–79.
Goldstein SA, Bockenhauer D, O’Kelly I, Zilberberg N. Potassium leak channels and the KCNK family of two-p-domain subunits. Nat Rev Neurosci. 2001;2:175–84.
Judge SI, Smith PJ, Stewart PE, Bever CT Jr. Potassium channel blockers and openers as CNS neurologic therapeutic agents. Recent Pat CNS Drug Discov. 2007;2:200–28.
Patel AJ, Honoré E. Anesthetic-sensitive 2P domain K+ channels. Anesthesiology. 2001;95:1013–21.
Patel AJ, Honoré E, Lesage F, Fink M, Romey G, Lazdunski M. Inhalational anesthetics activate two-pore-domain background K+ channels. Nat Neurosci. 1999;2:422–6.
Lesage F. Pharmacology of neuronal background potassium channels. Neuropharmacology. 2003;44:1–7.
Enyedi P, Czirják G. Molecular background of leak K+ currents: two-pore domain potassium channels. Physiol Rev. 2010;90:559–605.
Yost CS. Tandem pore domain K channels: an important site of volatile anesthetic action? Curr Drug Targets. 2000;1:207–17.
Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004;23:2684–95.
Sirois JE, Lei Q, Talley EM, Lynch C 3rd, Bayliss DA. The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics. J Neurosci. 2000;20:6347–54.
Punke MA, Licher T, Pongs O, Friederich P. Inhibition of human TREK-1 channels by bupivacaine. Anesth Analg. 2003;96:1665–73.
Patel AJ, Honoré E, Maingret F, Lesage F, Fink M, Duprat F, Lazdunski M. A mammalian two pore domain mechano-gated S-like K+ channel. EMBO J. 1998;17:4283–90.
Du G, Chen X, Todorovic MS, Shu S, Kapur J, Bayliss DA. TASK channel deletion reduces sensitivity to local anesthetic-induced seizures. Anesthesiology. 2011;115:1003–11.
Buyse I, Stockman W, Columb M, Vandermeersch E, Van de Velde M. Effect of sufentanil on minimum analgesic concentrations of epidural bupivacaine, ropivacaine and levobupivacaine in nullipara in early labour. Int J Obstet Anesth. 2007;16:22–8.
Acknowledgments
This work was supported by the World Class Institute (WCI 2009-003) and MRC (2012-0000305) Programs of the NRF funded by the MEST of Korea.
Conflict of interest
All authors declare no financial interests.
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Shin, H.W., Soh, J.S., Kim, H.Z. et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth 28, 81–86 (2014). https://doi.org/10.1007/s00540-013-1661-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00540-013-1661-1